Current management of prolactinomas

Journal of Neuro-Oncology

Volumn 54, Issue 2, 2001, Pages 139-150

  Nomikos, P ^a   Buchfelder, M ^a   Fahlbusch, R ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Medical treatment; Pituitary adenoma; Prolactinoma; Surgical management

Indexed keywords

ANTINEOPLASTIC AGENT; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CYTOSTATIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; KIRIM; LISURIDE; LISURIDE MALEATE; METERGOLINE; PROLACTIN; QUINAGOLIDE;

ANTINEOPLASTIC ACTIVITY; AUTOPSY; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SIZE; CANCER SURGERY; CAVERNOUS SINUS; CLINICAL FEATURE; DRUG EFFECT; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; LONG TERM CARE; MALE SEXUAL DYSFUNCTION; MENSTRUATION DISORDER; OPTIC NERVE; ORTHOSTATIC HYPOTENSION; PROLACTIN BLOOD LEVEL; PROLACTINOMA; REVIEW; SELLA TURCICA; TRANSSPHENOIDAL SURGERY;

ANIMALS; FEMALE; HUMANS; PITUITARY NEOPLASMS; PREGNANCY; PROLACTINOMA;

EID: 0035179230     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012905415868     Document Type: Review

References (77)

1. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series
2. Sellar lesions associated with isolated hyperprolactinaemia. Morphological, immunocytochemical, hormonal and clinical results
3. Transsphenoidal surgery of hypersecreting pituitary tumors
4. Galactorrhea: Successful treatment with reduction of plasma prolactin levels by bromocriptine
5. Pituitary tumors and pregnancy
6. Operating characteristics of the hypothalamo-pituitary-gonadal axis in men: Circadian, ultradian, and pulsatile release of prolactin and its temporal coupling with luteinizing hormone
7. The anterior pituitary
8. Neuroendocrinology of pituitary hormone regulation
9. A prolactin-inhibiting factor within the precursor for human gonadotropin-releasing hormone
10. Results of treatment of pituitary disease in multiple endocrine neoplasia, type I
11. The classification and molecular biology of pituitary adenomas
12. Clonal origin of pituitary adenomas
13. Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors
14. Ectopic hormone production by endocrine tumors: Localization of hormones at the cellular level by immunocytochemistry
15. Graded hyperprolactinemia first suppresses LH pulse frequency and then pulse amplitude in castrated rats
16. Ovulation and normal luteal function during LHRH treatment of women with hyperprolactinaemic amenorrhoea
17. Effects of prolactin and estrogen deficiency in amenorrheic bone loss
18. An autopsy case of invasive pituitary adenoma (prolactinoma) with rapid fatal clinical course due to streptococcal meningitis
19. Diagnosis and treatment of prolactinomas
20. Postoperative evaluation of dopaminergic tone in prolactinoma patients. II. Plasma thyrotropin response to metoclopramide
21. Thyrotropin alpha- and beta-subunit responses to thyrotropin-releasing hormone and domperidone in normal subjects and in patients with microprolactinomas
22. The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: Relationship to adenoma size at surgery
23. Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings
24. Recent advances in CT and MRI in the diagnosis and follow-up of hypothalamo-pituitary disease
25. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas
26. The natural history of untreated hyperprolactinemia: A prospective analysis
27. Natural history of microprolactinomas: Six-year follow-up
28. The inhibition of prolactin secretion in man by CB-154 (2-Br-alpha-ergocryptine)
29. Bromocriptine reduces pituitary tumor size and hypersection. Requiem for pituitary surgery?
30. The effect of lisuride hydrogen maleate in the hyperprolactinaemia-amenorrhoea syndrome: Clinical and hormonal responses
31. Treatment of hyperprolactinaemia with pergolide mesylate: Acute effects and preliminary evaluation of long-term treatment
32. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride
33. Inhibitory effect of cabergoline on the development of estrogen-induced prolactin-secreting adenomas of the pituitary
34. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients
35. CV 205-502 treatment of hyperprolactinemia
36. CV 205-502: A new long-acting drug for inhibition of prolactin hypersecretion
37. Dopaminergic inhibition of prolactin synthesis and prolactin messenger RNA accumulation in cultured pituitary cells
38. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study
39. Human prolactin-producing adenomas and bromocriptine: A histological, immunocytochemical, ultrastructural, and morphometric study
40. Perivascular fibrosis in prolactinomas: Is it increased by bromocriptine?
41. Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy
42. Bromocriptine: Does it jeopardise the result of later surgery for prolactinomas?
43. Prolactinomas
44. Pathologic hyperprolactinemia
45. Dopamine agonists and pituitary tumor shrinkage
46. Resistance to bromocriptine in prolactinomas
47. TRH test for prolactinoma
48. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients
49. Macroprolactinomas: Persistent normoprolactinemia and disappearance of tumour on MR images after short-term medical treatment with dopamine agonists
50. Rhinorrhea following dopamine agonist therapy of invasive macroprolactinoma
51. Cerebrospinal fluid rhinorrhea caused by bromocriptine therapy of prolactinoma
52. Cabergoline and quinagolide therapy for prolactinomas
53. Prolactinomas: Preoperative bromocriptine treatment. Surgical results
54. Surgical complications
55. Complications of trans-sphenoidal surgery
56. Surgical results for pituitary adenomas: Results of an international survey
57. Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas
58. Results of surgery in 114 patients with prolactin-secreting pituitary adenomas
59. Endocrine outcome after transsphenoidal adenomectomy for prolactinoma: Prolactin levels and tumor size as predicting factors
60. Prolactin-secreting pituitary adenomas: Transsphenoidal microsurgical treatment
61. Cavernous sinus invasion by pituitary adenomas
62. Proliferation parameters for pituitary adenomas
63. Management of prolactinomas associated with very high serum prolactin levels
64. Influence of previous bromocriptine therapy on surgery for microprolactinoma
65. Surgical outcome and pathological effects of bromocriptine preoperative treatment in prolactinomas
66. Short-term preoperative treatment of macroprolactinomas by dopamine agonists
67. Differentiated therapy of microprolactinomas: Significance of transsphenoidal adenomectomy
68. Galactorrhea-amenorrhea syndrome: Follow-up of forty-five patients after pituitary tumor removal
69. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma
70. Present status of neurosurgery in the treatment of prolactinomas
71. Recurrence after transsphenoidal surgery for pituitary adenomas
72. Pituitary adenoma: The efficacy of radiotherapy as the sole treatment
73. Megavoltage pituitary irradiation in the management of prolactinomas: Long-term follow-up
74. Treatment of prolactinomas with megavoltage radiotherapy
75. Gamma knife radiosurgery for prolactinomas
76. Pregnancy and the hyperprolactinemic woman
77. Bromocriptine in pregnancy: Safety aspects